Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

PFIZER INC : Other Events (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 06:48am EST

Item 8.01 Other Events On December 7, 2018, Pfizer Inc. ("Pfizer") issued a notice for the redemption in full of all €1,141,300,000 aggregate principal amount outstanding of its 5.750 per cent. Notes due 2021 (ISIN: XS0432071131; COMMON CODE: 043207113) (the "Notes").

The Notes will be redeemed on January 9, 2019 at a "make-whole" redemption price as set forth in the indenture, as supplemented, pursuant to which the Notes were issued. On the redemption date, the redemption price will become due and payable on the Notes and, unless Pfizer defaults in the payment of the redemption price, interest on the Notes will cease to accrue on and after the redemption date. The notice of redemption specifying the terms, conditions and procedures for the redemption is available through The Bank of New York Mellon, located at 240 Greenwich St., New York, New York 10286, as paying agent for the Notes. The foregoing does not constitute a notice of redemption for the Notes.

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
02/23PFIZER : Ochsner Health System and Pfizer team up to rethink clinical trials
AQ
02/23PFIZER : G-CON delivers cleanroom POD with tablet coating capability to Pfizer
AQ
02/22PFIZER : Lilly, Pfizer say NGF drug works in back pain too
AQ
02/21PFIZER : Ochsner Health System and Pfizer Partner to Develop Innovative Models f..
AQ
02/21CYTODYN INC. : - Leronlimab reduces by more than 98% human breast cancer metasta..
AQ
02/21PFIZER : and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in ..
AQ
02/20PFIZER : Sales of generic oncology drugs surge
AQ
02/20PFIZER : Pivotal Phase III Data for BAVENCIO (avelumab) Plus INLYTA (axitinib) i..
AQ
02/19RECENT RESEARCH AND THE CURRENT SCEN : Otsuka, astrazeneca, pfizer, eli lilly
AQ
02/19PFIZER : Ochsner Health System and Pfizer Partner to Develop Innovative Models f..
BU
More news
Financials ($)
Sales 2019 53 177 M
EBIT 2019 19 894 M
Net income 2019 12 226 M
Debt 2019 29 742 M
Yield 2019 3,35%
P/E ratio 2019 19,75
P/E ratio 2020 16,54
EV / Sales 2019 5,24x
EV / Sales 2020 5,12x
Capitalization 249 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 44,2 $
Spread / Average Target 2,9%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-3.46%249 168
JOHNSON & JOHNSON5.85%363 785
ROCHE HOLDING LTD.13.89%238 335
NOVARTIS8.12%231 565
MERCK AND COMPANY5.71%210 032
ELI LILLY AND COMPANY6.05%128 392